Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Milestone PharmaceuticalsMIST +0.08%22 Equity-to-Asset is 0.10 as of Jun. 2026, which is 78% below its 10-year median of 0.45. GuruFocus rates MIST with a GF Score™ of 22/100. The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Milestone Pharmaceuticals ranks worse than 84.96% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Milestone Pharmaceuticals Equity-to-Asset Related Terms
Milestone Pharmaceuticals Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIST vs UNCY, CNTB, EQ: Equity-to-Asset Comparison
For the Biotechnology subindustry, Milestone Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Milestone Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Milestone Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Milestone Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Pharmaceuticals (MIST) has a Equity-to-Asset of 0.10 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Milestone Pharmaceuticals and its competitors. This is 78% below median its historical median of 0.45. According to the industry distribution chart, Milestone Pharmaceuticals ranks #1198 out of 1410 companies in the Biotechnology industry, placing it in the top 85%.
Is Milestone Pharmaceuticals' Equity-to-Asset too high?
Milestone Pharmaceuticals' current Equity-to-Asset of 0.10 is 78% below median its 10-year median of 0.45. The Biotechnology industry median Equity-to-Asset is 0.69. Milestone Pharmaceuticals' value of 0.10 is 85.5% below this industry median. Based on the distribution chart, Milestone Pharmaceuticals ranks #1198 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Milestone Pharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Milestone Pharmaceuticals' Equity-to-Asset compare to UNCY and CNTB?
According to the Biotechnology industry distribution chart, Milestone Pharmaceuticals ranks #1198 out of 1410 companies for Equity-to-Asset. This places Milestone Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Milestone Pharmaceuticals' value of 0.10 is 85.5% below this benchmark. While the company's 10-year median is 0.45 vs. the industry median of 0.69, Milestone Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Milestone Pharmaceuticals's current Equity-to-Asset of 0.10 is 85.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Milestone Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Milestone Pharmaceuticals's current Equity-to-Asset is 0.10, which is 78% below median its own 10-year median of 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Milestone Pharmaceuticals stock overvalued right now?
Milestone Pharmaceuticals (MIST) has a current Equity-to-Asset of 0.10. The current Equity-to-Asset is 0.10, which is 78% below median its 10-year median of 0.45 and 85.5% below the Biotechnology industry median of 0.69. Milestone Pharmaceuticals' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Milestone Pharmaceuticals (MIST), the current Equity-to-Asset is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Canada that develops therapies for cardiovascular conditions. Its lead candidate is etripamil, a self-administered nasal spray being developed as an at-home treatment for paroxysmal supraventricular tachycardia (PSVT), a rapid heart rhythm disorder that currently often requires emergency department care. The company is also exploring etripamil for other cardiac arrhythmias, including atrial fibrillation with rapid ventricular rate. Milestone operates as a single reporting segment and generates no product revenue, relying on equity financings and partnerships to fund research, development, and regulatory activities. Its activities span clinical trials and regulatory submissions primarily in the United States and Canada, with a focus on shifting episodic cardiac care from hospital settings to patient self-management. The company has pursued commercialization partnerships to support potential launch and distribution of etripamil if approved.
22GF Score
Get the complete analysis for MIST
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIST has been successfully added to your 
